Cadwalader, Wickersham & Taft and Ropes & Gray are advising on an agreement between biotechnology giants Biogen Idec and Elan that will see the former spend at least $3.25 billion to acquire full rights to the drug Tysabri, which is used to treat multiple sclerosis and Crohn’s disease.
Tysabri, which generated $1.6 billion in sales in 2012, has been Biogen’s best-selling drug, according to Bloomberg. The company has been splitting profits from Tysabri equally with Elan, an Irish drugmaker that has now essentially become an investment vehicle after selling its sole remaining asset. While the market reaction has been harsh to Elan’s decision to sell its rights to Tysabri for $3.25 billion in cash plus future royalties, Reuters reports that the Dublinbased company will use the proceeds to acquire new drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
